Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $181.5 million.

  • Viking Therapeutics' Change in Acquisitions & Divestments rose 317.99% to $181.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.9 million, marking a year-over-year increase of 4313.8%. This contributed to the annual value of $560.0 million for FY2024, which is 8715.58% up from last year.
  • Latest data reveals that Viking Therapeutics reported Change in Acquisitions & Divestments of $181.5 million as of Q3 2025, which was up 317.99% from $166.0 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Change in Acquisitions & Divestments peaked at $295.9 million during Q1 2025, and registered a low of $32.3 million during Q1 2022.
  • Its 5-year average for Change in Acquisitions & Divestments is $99.2 million, with a median of $63.2 million in 2021.
  • In the last 5 years, Viking Therapeutics' Change in Acquisitions & Divestments crashed by 6185.28% in 2021 and then soared by 16304.64% in 2024.
  • Viking Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $63.0 million in 2021, then fell by 17.65% to $51.9 million in 2022, then surged by 156.94% to $133.3 million in 2023, then rose by 7.71% to $143.5 million in 2024, then grew by 26.43% to $181.5 million in 2025.
  • Its Change in Acquisitions & Divestments was $181.5 million in Q3 2025, compared to $166.0 million in Q2 2025 and $295.9 million in Q1 2025.